Related Experiment Video

Updated: Jul 16, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

[The relationship between prion protein gene codon 129 polymorphism and Alzheimer's disease]

Hai-rong Qian1, Lu-ning Wang, Ming-wei Zhu

  • 1Department of Geriatric Neurology, General Hospital of PLA, Beijing 100853, China.

Zhonghua Nei Ke Za Zhi
|February 23, 2007
PubMed
Abstract

Insights

This meta-analysis found no significant link between prion protein gene (PRNP) codon 129 homozygosity and Alzheimer's disease (AD) risk in Europeans. However, M/* genotypes showed increased AD risk, while V/* genotypes indicated a decreased risk.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Context:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • The prion protein gene (PRNP) codon 129 polymorphism is investigated for its potential role in AD pathogenesis.
  • Understanding genetic risk factors is crucial for developing targeted therapies.

Purpose:

  • To conduct a meta-analysis examining the association between PRNP codon 129 polymorphism and Alzheimer's disease.
  • To synthesize evidence from existing studies to determine the genetic contribution of PRNP codon 129 to AD risk.
  • To clarify the role of different PRNP codon 129 genotypes (MM, MV, VV) in AD susceptibility.

Summary:

  • A meta-analysis of 3 studies (972 AD cases, 658 controls) was performed.
  • No significant association was found between PRNP codon 129 homozygosity (MM or VV) and AD onset.
  • The M/* genotype was associated with an increased risk of AD, whereas the V/* genotype was linked to a decreased risk.

Impact:

  • Provides insights into the complex genetic landscape of Alzheimer's disease.
  • Suggests that PRNP codon 129 polymorphism may influence AD risk differently based on genotype combinations.
  • Highlights the need for further research into the specific mechanisms underlying these associations.

More Related Videos

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...